Inspire Medical SystemsINSP
Recorded

Inspire Medical Systems Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration34 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Jonathan BlockAnalyst

Jon Block with Stifel, and I am happy to introduce the team from Inspire Medical. Tim Herbert, Chairman and CEO, Matt Osberg, CFO. We are going to do predominantly Q&A, but I just spoke to Tim. We are going to kick things off with a couple slides. I will hand the floor over to Tim. We will go over a couple slides, and then we will jump into Q&A from there.

Tim HerbertCEO

Very good, Jon. Thank you very much for hosting us again this year.

Tim HerbertCEO

Yeah. We really enjoy this conference and enjoy having all the meetings that we have had with everybody today. It has been very informative.

Tim HerbertCEO

I just have to click on that. Or is he driving it?

Jonathan BlockAnalyst

I think we are trying to rectify the- We're trying to sign up for a free trial.

Tim HerbertCEO

What if we learn more?

Jonathan BlockAnalyst

How are we doing back there on the slides?

Jonathan BlockAnalyst

Working on it. Okay. Yeah.

Tim HerbertCEO

There we go. Go ahead. Okay, advance the slide again, if you will. One more. There we go.

Tim HerbertCEO

There we go. Quickly, just a quick overview. We really have an under-penetrated market right now, and I know we've had challenges over the last two years in continuing to grow our adoption, but we've always continued to focus on the clinical evidence. We have over 400 publications and more really important publications forthcoming. We're up to 1,300 employees, and most recently on the bottom, we just announced we've crossed over 150,000 patients have received Inspire therapy. What's so important to the team at Inspire and all the employees and the healthcare providers, it's all about clinical outcomes. With clinical outcomes, we can push the adoption as fast as we want, as long as we never give up on the patients. What's so unique about hypoglossal nerve stimulation is you need to identify when the patient inhales, because that's when the airway is susceptible to collapse.

Tim HerbertCEO

We have a sensing capability, and so when the patient inhales, that's when we provide stimulation to the hypoglossal nerve to maintain an open airway. Now, what we've done with Inspire V, our fifth-generation device, we've taken a sensor that used to be placed between the intercostal muscles in a patient's chest, and we relocated that using an accelerometer that is now inside the neurostimulator, inside the body of the patient. Same technology that you see with cardiac pacemakers when we do rate-responsive pacing. As the patient goes jogging, it measures its respiratory rate and paces faster. We can use that same technology to measure respiration. What we found is it's a much more stable environment. You see how we measure this called inspiratory overlap, and what percent of the inspiratory cycle do we provide stimulation to maintain an open airway.

Tim HerbertCEO

You can see we've improved that from 79% all the way to 87% with Inspire V. That translates into reductions in the severity of sleep, specifically in this case, the apnea-hypopnea index. The data that you see here is from a clinical study that was run in Singapore and will be published in the very near future. Couple key catalysts and updates that I'm sure Jon Block will have several questions on. This year has all been about reimbursement. We've had challenges with transitioning to Inspire V and what code to be able to use. When we went back to the code 64568 that everybody has heard us talk about so frequently during the year, there were challenges using that code and the reimbursement, so we needed to develop a new code as we progressed into 2026.

Tim HerbertCEO

We were solving that with three steps, near term, medium term, and long term. The near term was there's temporary codes in place that centers can use to bill for an Inspire V. Those codes are in place. They've been educated with centers, and centers now know what code they need to use to be able to bill an Inspire V. Midterm is we want to improve the reimbursement at facilities. That came through last Thursday. Our earnings call was last Monday. Since then, last Thursday, we received the data that the OPPS or the reimbursement to the facilities for Inspire went up significantly. In fact, hospital reimbursement went up 11%, and reimbursement in the ambulatory surgical center went up 13.5%. That's really significant as we move forward. Of course, long term is a brand new CPT Category I code that was recently awarded.

Tim HerbertCEO

In fact, we're right in the process right now for that code being valued, and that code will take effect January 1st, 2028. I already mentioned the Inspire V and the clinical data that we had. This was recently presented at the ENT conferences. There's two of them, the AAO and the ISSS meeting. Project Horizon, Matt Osberg will talk a little bit more about this, but as we continue to grow, we took the opportunity to look for efficiencies in our organization. We identified $30 million of efficiencies that we can reallocate towards growth, and we'll let Matt Osberg talk more about that. We're going to keep working on expanding our clinical evidence. It's about Inspire V performance that I mentioned. Talk about the physiologic disease impact. What's more important, it's not just about AHI, apnea-hypopnea index. It's about that term you see there, hypoxic burden.

Tim HerbertCEO

That's the challenge that the body, it's the stress the body is under during a night of sleep with apneic events with the oxygen desaturating, and that has direct correlation with cardiovascular health and systemic outcomes. Finally, what we can do with this is work more so with patient identification and access to care. Quite a bit more moving forward on that. Let me hand it off to Matt Osberg for a summary of some financials.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day